BE2017C027I2 - - Google Patents

Download PDF

Info

Publication number
BE2017C027I2
BE2017C027I2 BE2017C027C BE2017C027C BE2017C027I2 BE 2017C027 I2 BE2017C027 I2 BE 2017C027I2 BE 2017C027 C BE2017C027 C BE 2017C027C BE 2017C027 C BE2017C027 C BE 2017C027C BE 2017C027 I2 BE2017C027 I2 BE 2017C027I2
Authority
BE
Belgium
Application number
BE2017C027C
Other languages
French (fr)
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Publication of BE2017C027I2 publication Critical patent/BE2017C027I2/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0002General or multifunctional contrast agents, e.g. chelated agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032Methine dyes, e.g. cyanine dyes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806Suspensions, emulsions, colloids, dispersions
    • A61K49/1812Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0085Brain, e.g. brain implants; Spinal cord
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277Preparation processes; Proliposomes
    • A61K9/1278Post-loading, e.g. by ion or pH gradient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BE2017C027C 2004-05-03 2017-07-10 BE2017C027I2 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56792104P 2004-05-03 2004-05-03
US11/601,451 US8658203B2 (en) 2004-05-03 2006-11-17 Liposomes useful for drug delivery to the brain

Publications (1)

Publication Number Publication Date
BE2017C027I2 true BE2017C027I2 (cs) 2024-08-08

Family

ID=46045566

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2017C027C BE2017C027I2 (cs) 2004-05-03 2017-07-10

Country Status (2)

Country Link
US (3) US8658203B2 (cs)
BE (1) BE2017C027I2 (cs)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
HUE068934T2 (hu) * 2004-05-03 2025-02-28 Ipsen Biopharm Ltd Liposzómák gyógyszerbejuttatásra
GEP20094620B (en) * 2004-06-01 2009-02-25 Yakult Honsha Kk Irinotecan preparation
WO2006042090A1 (en) 2004-10-05 2006-04-20 Avigen, Inc. Stepped cannula
WO2007024841A2 (en) 2005-08-23 2007-03-01 The Regents Of The University Of California Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery
US20140335166A1 (en) * 2013-05-08 2014-11-13 Michael W. Fountain Methods of Making and Using Nano Scale Particles
US20080305157A1 (en) * 2007-06-08 2008-12-11 University Of Maryland Office Of Technology Commercialization Encapsulation and separation of charged organic solutes inside catanionic vesicles
WO2009033176A1 (en) * 2007-09-07 2009-03-12 The Trustees Of The University Of Pennsylvania A method of targeting a transferrin receptor
US9550827B2 (en) 2007-10-19 2017-01-24 The Regents Of The University Of California Methods for ameliorating and preventing central nervous system inflammation
CA2706111C (en) * 2007-12-04 2013-06-18 Bracco Imaging S.P.A. Homogenization of a radiopharmaceutical using sonification and/or rotor-stator technology to produce a homogenous suspension, emulsion, mixture or solid suspension of immiscible ingredients
AR076634A1 (es) * 2008-11-21 2011-06-29 Medgenesis Therapeutix Inc Composiciones y metodo para tratar desordenes del sistema nervioso central
JP5588619B2 (ja) 2009-03-11 2014-09-10 一丸ファルコス株式会社 pH応答性リポソーム
DE102009031274A1 (de) * 2009-06-30 2011-01-13 Justus-Liebig-Universität Giessen Liposomen zur pulmonalen Applikation
PL2558154T3 (pl) 2010-04-16 2020-11-30 Clearpoint Neuro, Inc. Systemy chirurgiczne MRI zawierające kaniule chirurgiczne kompatybilne z MRI do transferu substancji do i/lub od pacjenta
CA2803317A1 (en) * 2010-06-19 2011-12-22 Western University Of Health Sciences Novel formulation of pegylated-liposome encapsulated glycopeptide antibiotics
CN104606142A (zh) * 2010-11-26 2015-05-13 约翰内斯堡威特沃特斯兰德大学 用于治疗阿尔茨海默病的可植入头颅中的装置
US10980798B2 (en) * 2011-11-03 2021-04-20 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
KR102107482B1 (ko) 2012-02-14 2020-05-08 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 심혈관 질환 및 다른 증상에 대한 파라크린 유전자의 전신 전달 및 조절 발현
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US20150306236A1 (en) * 2012-09-04 2015-10-29 Lauren Sciences Llc Bolaamphiphilic compounds, compositions and uses thereof
EP2892509B1 (en) * 2012-09-04 2024-12-11 Lauren Sciences LLC Bolaamphiphilic compounds, compositions and uses thereof
WO2014116866A1 (en) * 2013-01-24 2014-07-31 Memorial Sloan Kettering Cancer Center Method for diagnosing or treating tumors using sphingomyelin containing liposomes
EP4309657A3 (en) 2013-02-01 2024-02-28 Celator Pharmaceuticals, Inc. Remote loading of sparingly water-soluble drugs into liposomes
US9289502B2 (en) 2013-03-08 2016-03-22 Emerald Therapeutics, Inc. Preparation of oligo conjugates
EP2992000B1 (en) 2013-05-03 2020-07-08 The Regents of The University of California Cyclic di-nucleotide induction of type i interferon
US9891296B2 (en) 2013-09-13 2018-02-13 MRI Interventions, Inc. Intrabody fluid transfer devices, systems and methods
MX2016012558A (es) 2014-04-03 2017-01-09 Univ California Suministro sistemico de vectores de virus que codifican urocortina-2 y genes relacionados para tratar disfunciones cardiacas relacionadas con diabetes y falla de corazon congestivo.
AU2015301234A1 (en) 2014-08-04 2017-06-15 Zoneone Pharma, Inc. Remote loading of sparingly water-soluble drugs into lipid vesicles
US20160158154A1 (en) * 2014-12-05 2016-06-09 Georgia Tech Research Corporation Protein vesicles and methods of making and using thereof
WO2016094402A1 (en) * 2014-12-09 2016-06-16 Merrimack Pharmaceuticals, Inc. Treatment of breast cancer with liposomal irinotecan
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
SI3337467T1 (sl) 2015-08-20 2021-03-31 Ipsen Biopharm Ltd. Ash Road Kombinacijska terapija, ki vsebuje liposomski irinotekan in zaviralec PARP za zdravljenje raka
PT3337478T (pt) 2015-08-21 2020-10-19 Ipsen Biopharm Ltd Combinação de fármacos compreendendo irinotecano lipossómico, oxaliplatina, 5-fluorouracilo e leucovorina para o tratamento do cancro do pâncreas metastático
EP3337457A4 (en) * 2015-08-21 2019-01-02 University of Otago Acoustic driven drug delivery systems
US10123969B2 (en) 2015-10-15 2018-11-13 Wisconsin Alumni Research Foundation Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid
LT3362049T (lt) * 2015-10-16 2025-09-10 Ipsen Biopharm Ltd. Kamptotecino farmacinių kompozicijų stabilizavimas
WO2017100125A1 (en) 2015-12-10 2017-06-15 The Regents Of The University Of California Compositions and methods for treating or ameliorating neuroinflammation, neurodegeneration, neuropathic pain, and migraine
WO2017142698A1 (en) 2016-02-17 2017-08-24 MRI Interventions, Inc. Intrabody surgical fluid transfer assemblies with adjustable exposed cannula to needle tip length, related systems and methods
RU2761953C2 (ru) 2016-11-02 2021-12-14 Ипсен Биофарм Лтд. Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин)
EP3655021B1 (en) 2017-07-19 2023-03-22 Unikeris Limited Adenosine deaminase for treating or ameliorating scleroderma-associated vasculopathy
WO2019028697A1 (en) 2017-08-09 2019-02-14 Zte Corporation QUALITY OF SERVICE IMPROVEMENTS FOR SEPARATING A USER PLAN
JP6297737B1 (ja) * 2017-09-25 2018-03-20 ジェイ−ネットワーク,インコーポレイテッド 正に帯電した荷電ニオソームの調製方法及び荷電ニオソーム
EP3787601B1 (en) * 2018-04-30 2025-10-08 Purdue Research Foundation Liposomal nano formulation of combinational antibiotics and the uses thereof
US11253237B2 (en) 2018-05-09 2022-02-22 Clearpoint Neuro, Inc. MRI compatible intrabody fluid transfer systems and related devices and methods
US11022664B2 (en) 2018-05-09 2021-06-01 Clearpoint Neuro, Inc. MRI compatible intrabody fluid transfer systems and related devices and methods
EP3599243B1 (en) 2018-07-26 2023-04-12 CVIE Therapeutics Limited 17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure
TWI729562B (zh) * 2018-11-14 2021-06-01 台灣微脂體股份有限公司 包含用於治療因骨密度降低或軟骨損失導致之疾病的治療劑的緩釋藥物組合物及其用途
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
WO2020180356A1 (en) 2019-03-05 2020-09-10 Windtree Therapeutics, Inc. Istaroxime-containing intravenous formulation for the treatment of acute heart failure (ahf)
WO2021022088A1 (en) * 2019-08-01 2021-02-04 Incube Labs, Llc Intracranial delivery of medicinal solution
US11684750B2 (en) 2019-10-08 2023-06-27 Clearpoint Neuro, Inc. Extension tube assembly and related medical fluid transfer systems and methods
FI3805243T3 (fi) 2019-10-09 2024-02-07 Windtree Therapeutics Inc Androstaanijohdannaisia, joilla on aktiivisuus puhtaina tai pääasiallisesti puhtaina SERCA2a:n stimulaattoreina, sydämen vajaatoiminnan hoitoon
AU2021342431A1 (en) * 2020-09-16 2023-07-13 Imagion Biosystems, Inc. Methods and apparatuses for the synthesis of drug-loaded magnetic micelle aggregates
US20240148688A1 (en) 2021-02-01 2024-05-09 The Regents Of The University Of California Methods for treating and ameliorating cancer
CA3212101A1 (en) 2021-03-18 2022-09-22 Yury Miller Compositions and methods for targeting inflammatory or activated cells and treating or ameliorating inflammatory conditions and pain
CN115364218A (zh) * 2021-05-21 2022-11-22 杭州高田生物医药有限公司 一种特定药脂比的药物组合物在抗肿瘤中的应用
JP2024526956A (ja) 2021-07-22 2024-07-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 精製ヒトrna編集酵素を使用するための組成物および方法
WO2023118893A1 (en) * 2021-12-22 2023-06-29 Mycural Therapeutics Novel pyridocarbazolium compounds and medical uses thereof
CN116731010B (zh) * 2023-06-08 2025-02-11 西南大学 长春胺类衍生物及其制备方法和应用
CN116874540A (zh) * 2023-07-20 2023-10-13 上海灵瑞医药有限公司 硫酸酯三乙铵盐的合成方法
WO2025076208A1 (en) 2023-10-03 2025-04-10 Raft Pharmaceuticals, Inc. Compositions and methods for treating pain disorders
CN119909018B (zh) * 2025-04-01 2025-09-02 山东新时代药业有限公司 一种注射用氟维司群长效脂质体及其制备方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US578987A (en) * 1897-03-16 Mechanism for propelling vessels
US4192869A (en) 1977-09-06 1980-03-11 Studiengesellschaft Kohle Mbh. Controlled improvement of the O2 release by intact erythrocytes with lipid vesicles
DE2740053A1 (de) * 1977-09-06 1979-05-03 Klaus Prof Dr Med Gersonde Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten
US4397846A (en) 1981-05-15 1983-08-09 Murray Weiner Storage-stable lipid vesicles and method of preparation
US5059591B1 (en) * 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
US4649155A (en) 1983-07-22 1987-03-10 Hoffmann-La Roche Inc. Injectable solutions
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5736155A (en) * 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5043165A (en) * 1988-12-14 1991-08-27 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs
US4960790A (en) 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
ZA902710B (en) 1989-05-22 1991-12-24 Univ Georgia Res Found Enzyme luminescence assay
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
PL296382A1 (en) 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system
US5498420A (en) 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
JPH06511470A (ja) 1991-07-03 1994-12-22 ネクスター・フアーマシユーテイカルズ・インコーポレイテツド 薬剤を含むリポソームの調製における充填技術
US5281237A (en) * 1992-09-25 1994-01-25 Gimpelson Richard J Surgical stitching device and method of use
US6350853B1 (en) * 1993-04-26 2002-02-26 Peter E. Nielsen Conjugated peptide nucleic acids having enhanced cellular uptake
DE4320597A1 (de) 1993-06-22 1995-01-05 Heinz C Prof Dr Dr Schroeder Verwendung von Polyphosphaten zur antiviralen Therapie und als Immunmodulatoren
US6743917B2 (en) * 1993-06-30 2004-06-01 University Of Pittsburgh Camptothecin analogs and methods of preparation thereof
US5534241A (en) * 1993-07-23 1996-07-09 Torchilin; Vladimir P. Amphipathic polychelating compounds and methods of use
US5538954A (en) * 1994-06-24 1996-07-23 A/S Dumex (Dumex Ltd.) Salts of tetracyclines
CN1083713C (zh) * 1994-02-04 2002-05-01 利珀克尔集团公司 双层制剂
US5783568A (en) * 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
WO1996025147A1 (en) 1995-02-14 1996-08-22 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering liposome-loadable drugs
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
DE19605024A1 (de) 1996-01-31 1997-08-07 Schering Ag Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
DE69730218D1 (de) 1996-04-11 2004-09-16 Univ British Columbia Fusogene liposomen
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
WO1998017256A1 (en) 1996-10-22 1998-04-30 Dmitri Kirpotin Compound-loaded liposomes and methods for their preparation
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
JP2000516641A (ja) 1997-07-02 2000-12-12 エスディージー インコーポレイテッド 診断および治療用途の目標指向性リポソーム構成物
US6316612B1 (en) 1997-08-22 2001-11-13 Ribozyme Pharmaceuticals, Inc. Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides
US6083923A (en) 1997-10-31 2000-07-04 Isis Pharmaceuticals Inc. Liposomal oligonucleotide compositions for modulating RAS gene expression
RU2130771C1 (ru) 1998-06-01 1999-05-27 Автушенко Сергей Сергеевич Способ получения липосомальных препаратов
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
WO2000009071A2 (en) 1998-08-11 2000-02-24 All India Institute Of Medical Sciences A novel liposomal formulation useful in treatment of cancer and other proliferation diseases
JP4740455B2 (ja) 1998-08-12 2011-08-03 イーサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム 硫酸アンモニウム勾配を使用して調製されるリポソーム性ブピバカイン組成物
BR9914601A (pt) * 1998-09-16 2001-10-23 Alza Corp Inibidor de topoisomerase capturado por lipossoma
US6291676B1 (en) * 1999-03-03 2001-09-18 University Of Kentucky Research Foundation Water-soluble derivatives of camptothecin/homocamptothecin
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
WO2000066126A2 (en) 1999-04-29 2000-11-09 Alza Corporation Liposome compositions for improved drug retention
US20020049176A1 (en) * 1999-11-10 2002-04-25 Anderson Christen M. Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery
DE60123583T2 (de) 2000-02-04 2007-08-09 Lipoxen Technologies Ltd. Dehydratisierungs-/rehydratisierungsverfahren zur herstellung von liposome
NZ522766A (en) 2000-05-15 2005-09-30 Celgene Corp Compositions and methods for the treatment of colorectal cancer with irinotecan and thalidomide to reduce side effects
US6486320B2 (en) 2000-09-15 2002-11-26 Aventis Pharma S.A. Preparation of camptothecin and of its derivatives
AU2002225878A1 (en) 2000-11-02 2002-05-15 Smith Kline Beecham Corporation Receptor antagonist-lipid conjugates and delivery vehicles containing same
CN1294991C (zh) 2001-03-26 2007-01-17 阿尔扎公司 用于改善治疗物质的细胞内传递的脂质体组合物
WO2003030864A1 (en) 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
TWI235066B (en) * 2001-10-03 2005-07-01 Celator Technologies Inc Liposome loading with metal ions
US20030129224A1 (en) * 2001-11-13 2003-07-10 Paul Tardi Lipid carrier compositions and methods for improved drug retention
US20030220284A1 (en) * 2002-02-22 2003-11-27 Patricia Yotnda Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
US7084115B2 (en) 2002-04-29 2006-08-01 Oxyplus, Inc. Inositol pyrophosphates, and methods of use thereof
EP2823809B1 (en) 2002-06-28 2016-11-02 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
US20040243101A1 (en) * 2002-07-02 2004-12-02 Gillis Edward M. Minimally invasive drug delivery catheter
WO2004035032A2 (en) 2002-08-20 2004-04-29 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
CN101229127B (zh) 2002-11-26 2012-10-10 吉里德科学公司 脂质体制剂
JP2007522085A (ja) 2003-06-27 2007-08-09 スミスクライン・ビーチャム・コーポレイション 安定化されたトポテカンリポソーム組成物および方法
AU2004264857B2 (en) * 2003-07-09 2010-06-10 Sutter West Bay Hospitals Remote detection of substance delivery to cells
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
HUE068934T2 (hu) 2004-05-03 2025-02-28 Ipsen Biopharm Ltd Liposzómák gyógyszerbejuttatásra
WO2006042090A1 (en) * 2004-10-05 2006-04-20 Avigen, Inc. Stepped cannula
US20060129126A1 (en) * 2004-11-19 2006-06-15 Kaplitt Michael G Infusion device and method for infusing material into the brain of a patient
PL2289535T3 (pl) * 2004-12-21 2018-12-31 Musc Foundation For Research Development Kompozycje i sposoby wspomagania gojenia ran oraz regeneracji tkanek

Also Published As

Publication number Publication date
US8658203B2 (en) 2014-02-25
US20170035749A1 (en) 2017-02-09
US20140127136A1 (en) 2014-05-08
US20070110798A1 (en) 2007-05-17
US9737528B2 (en) 2017-08-22

Similar Documents

Publication Publication Date Title
BE2024C508I2 (cs)
BE2023C542I2 (cs)
BE2022C549I2 (cs)
BE2021C001I2 (cs)
BE2020C513I2 (cs)
BE2020C517I2 (cs)
BE2019C540I2 (cs)
BE2019C523I2 (cs)
BE2019C548I2 (cs)
BE2019C506I2 (cs)
BE2018C045I2 (cs)
BE2020C525I2 (cs)
BE2017C063I2 (cs)
BE2017C027I2 (cs)
BE2017C023I2 (cs)
BE2017C002I2 (cs)
BE2016C067I2 (cs)
BE2014C071I2 (cs)
BE2015C015I2 (cs)
BE2014C064I2 (cs)
BE2014C063I2 (cs)
BE2014C010I2 (cs)
BE2013C071I2 (cs)
BE2013C021I2 (cs)
BE2012C025I2 (cs)